Interestingly, a recent phase II study including patients with NASH reported that 12 weeks of treatment with licogliflozin, a dual SGLT1/2 inhibitor, reduced circulating ALT and hepatic fat assessed by MRI-PDFF (335). The gene discussed is SLC5A1; the disease is metabolic dysfunction-associated steatohepatitis.